Atea Pharma (AVIR) Q3 2026 Earnings Call Transcript
Phase 3 hepatitis C data met its endpoints and funding now extends into mid-2028.
We haven't written up this one. Motley Fool has the full story — the link below goes straight to it.
More in Finance & Markets
TransMedics: 3 Key Takeaways for Long-Term Investors
Its ENHANCE heart and DENOVO lung programs target thousands of procedures that currently use no machine preservation at all.
- TransMedics revenue grew 41% YoY to $203 million in Q3 2026
- CEO Waleed Hassanein focuses on ENHANCE and DENOVO clinical programs
- Portable kidney system development for discarded kidneys
Ringgit opens marginally higher against greenback amid cautious market sentiment
KUALA LUMPUR: The ringgit opened marginally higher against the US dollar on Tuesday amid cautious market sentiment as investors continued to assess global economic developments and the outlook for US…
Samsung Fire & Marine Insurance to Take Control of Lloyd’s Insurer Canopius in Global Expansion Push
Samsung Fire & Marine Insurance is set to take control of UK-based specialty insurer Canopius, marking a major step in its strategy to strengthen its global presence and expand its overseas insurance…
- Samsung Fire & Marine to acquire 80.6% stake in Canopius
- KKR and KIC to invest 12.1% and 7.3% respectively
- Deal aims to expand Samsung's international specialty insurance presence
SIGA (SIGA) Q3 2026 Earnings Call Transcript
Zero debt and a new Canadian deal stand out, but U.S. contract timing remains unclear.
WhiteHorse (WHF) Q3 2026 Earnings Call Transcript
Board forms committee to explore strategic alternatives, including a sale.